成纤维细胞生长因子23与危重患者死亡相关
在两项危重患者队列(n=1527)中,较高的血浆FGF23水平与60天死亡率独立相关。在需要RRT的AKI患者(ATN研究)和普通危重患者(VALID研究)中,cFGF23和iFGF23最高四分位组死亡风险均显著高于最低四分位组,而PTH、维生素D代谢物、钙和磷水平与死亡率无关。
要点
- 危重患者中,cFGF23和iFGF23最高四分位组60天死亡风险显著增加。
- 在需要RRT的AKI患者和普通危重患者中,FGF23与死亡关联一致。
- PTH、维生素D代谢物、钙和磷水平与60天死亡率无关。
核心结论
- 较高的FGF23水平与危重患者更高的死亡率独立相关。
研究设计与样本
- 研究纳入两个危重患者队列共1527例,包括ATN研究中817例需要RRT的AKI患者和VALID研究中710例伴或不伴AKI的患者。
- 测量入组时血浆FGF23及其他矿物质代谢物水平,假设较高的FGF23水平与更高的60天死亡率独立相关。
主要发现
- ATN研究中,调整人口学、合并症和疾病严重程度后,cFGF23最高与最低四分位组比较的死亡比值比为3.84(95%CI 2.31-6.41),iFGF23为2.08(95%CI 1.03-4.21)。
- VALID研究中,调整后cFGF23最高与最低四分位组比较的死亡比值比为3.52(95%CI 1.96-6.33),iFGF23为1.93(95%CI 1.12-3.33)。
- 两个队列中,血浆/血清PTH、维生素D代谢物、钙和磷水平均与60天死亡率无关。
临床怎么用
- 对危重患者,尤其需要RRT的AKI患者,检测血浆FGF23水平可能有助于死亡风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Dysregulated mineral metabolism is a common and potentially maladaptive feature of critical illness, especially in patients with AKI, but its association with death has not been comprehensively investigated. We sought to determine whether elevated plasma levels of the osteocyte-derived, vitamin D-regulating hormone, fibroblast growth factor 23 (FGF23), are prospectively associated with death in critically ill patients with AKI requiring RRT, and in a general cohort of critically ill patients with and without AKI. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We measured plasma FGF23 and other mineral metabolite levels in two cohorts of critically ill patients (n=1527). We included 817 patients with AKI requiring RRT who enrolled in the ARF Trial Network (ATN) study, and 710 patients with and without AKI who enrolled in the Validating Acute Lung Injury biomarkers for Diagnosis (VALID) study. We hypothesized that higher FGF23 levels at enrollment are independently associated with higher 60-day mortality. RESULTS: In the ATN study, patients in the highest compared with lowest quartiles of C-terminal (cFGF23) and intact FGF23 (iFGF23) had 3.84 (95% confidence interval, 2.31 to 6.41) and 2.08 (95% confidence interval, 1.03 to 4.21) fold higher odds of death, respectively, after adjustment for demographics, comorbidities, and severity of illness. In contrast, plasma/serum levels of parathyroid hormone, vitamin D metabolites, calcium, and phosphate were not associated with 60-day mortality. In the VALID study, patients in the highest compared with lowest quartiles of cFGF23 and iFGF23 had 3.52 (95% confidence interval, 1.96 to 6.33) and 1.93 (95% confidence interval, 1.12 to 3.33) fold higher adjusted odds of death. CONCLUSIONS: Higher FGF23 levels are independently associated with greater mortality in critically ill patients.
引用
- Leaf DE, Siew ED, Eisenga MF, et al. Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. Clin J Am Soc Nephrol. 2018. PMID: 29519954. doi:10.2215/CJN.10810917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。